

By: **Senator Frosh**

Introduced and read first time: February 5, 1999

Assigned to: Judicial Proceedings

A BILL ENTITLED

1 AN ACT concerning

2 **The Decisionally Incapacitated Research Subject Protection Act**

3 FOR the purpose of specifying certain requirements for research involving certain
4 individuals with a potential or actual decisional incapacity; specifying certain
5 general conditions for certain investigators concerning research involving
6 certain decisionally incapacitated individuals and potentially decisionally
7 incapacitated individuals; specifying certain standards for investigators and
8 institutional review boards concerning the recruitment for certain purposes of
9 individuals with a potentially incapacitating condition; providing for the
10 execution and effect of a certain research advance directive under certain
11 circumstances; specifying certain duties of an investigator, institutional review
12 board, and medically responsible clinician concerning research involving a
13 decisionally incapacitated individual; providing for a certain process of informed
14 consent and assent concerning certain research involving a decisionally
15 incapacitated individual; authorizing a certain research agent, health care
16 agent, surrogate, proxy decision maker, or legally authorized representative to
17 provide a consent to participation in certain research by a decisionally
18 incapacitated individual under certain circumstances; providing for disclosure to
19 the public of certain information concerning research approved by an
20 institutional review board after a certain date; requiring a certain institutional
21 review board to submit a certain annual report to the Secretary of Health and
22 Mental Hygiene and the Attorney General; specifying certain powers and duties
23 of the Secretary and certain duties of the Attorney General; providing for certain
24 immunities, liabilities, disciplinary action, and penalties for certain persons;
25 requiring the effectiveness of a certain advance research directive made before a
26 certain date; making certain legislative findings; providing for the scope of this
27 Act and of certain provisions of this Act; defining certain terms; and generally
28 relating to certain research involving certain individuals with certain
29 incapacities.

30 BY adding to

31 Article - Health - General

32 Section 20-701 through 20-766, inclusive, to be under the new subtitle "Subtitle

33 7. Research Involving Decisionally Incapacitated Individuals"

34 Annotated Code of Maryland

1 (1996 Replacement Volume and 1998 Supplement)

2 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
3 MARYLAND, That the Laws of Maryland read as follows:

4 **Article - Health - General**

5 SUBTITLE 7. RESEARCH INVOLVING DECISIONALLY INCAPACITATED INDIVIDUALS.

6 PART I. GENERAL PROVISIONS.

7 20-701.

8 (A) IN THIS SUBTITLE THE FOLLOWING TERMS HAVE THE MEANINGS
9 INDICATED.

10 (B) "ASSENT" MEANS AN AFFIRMATIVE AGREEMENT OF AN INDIVIDUAL TO
11 PARTICIPATE IN RESEARCH.

12 (C) "COMMON RULE" MEANS THE FEDERAL REGULATIONS GOVERNING THE
13 PROTECTION OF A HUMAN SUBJECT IN RESEARCH CODIFIED AT 45 C.F.R. PART 46,
14 SUBPART A.

15 (D) "DECISIONAL INCAPACITY" MEANS A MEDICAL CONDITION THAT HAS
16 CAUSED AN INDIVIDUAL TO BE UNABLE TO UNDERSTAND SUFFICIENTLY THE
17 NATURE, EXTENT, OR PROBABLE CONSEQUENCES OF PARTICIPATION IN RESEARCH,
18 MAKE A SUFFICIENT EVALUATION OF BURDENS, RISKS, AND BENEFITS OF
19 PARTICIPATION IN RESEARCH, OR COMMUNICATE A DECISION ABOUT
20 PARTICIPATION IN RESEARCH.

21 (E) "DECISIONALLY INCAPACITATED INDIVIDUAL" MEANS AN INDIVIDUAL
22 WHO IS AT LEAST 18 YEARS OF AGE AND WHO CAN NOT GIVE A VALID INFORMED
23 CONSENT FOR RESEARCH PARTICIPATION BECAUSE THE INDIVIDUAL HAS A
24 DECISIONAL INCAPACITY.

25 (F) "DISINTERESTED INDIVIDUAL" MEANS AN INDIVIDUAL 18 YEARS OF AGE
26 OR OLDER WHO:

27 (1) DOES NOT PARTICIPATE IN ANY WAY, INCLUDING AUTHORSHIP OF A
28 PUBLICATION, IN RESEARCH ABOUT WHICH THE INDIVIDUAL PERFORMS A DUTY
29 UNDER THIS SUBTITLE;

30 (2) IS NOT EMPLOYED BY:

31 (I) THE SAME INSTITUTION OR CORPORATION THAT EMPLOYS AN
32 INVESTIGATOR INVOLVED IN THE RESEARCH; OR

33 (II) A HOSPITAL OR OTHER HEALTH CARE FACILITY IN WHICH A
34 POTENTIAL RESEARCH SUBJECT IS A PATIENT OR RESIDENT;

1 (3) DOES NOT RECEIVE, DIRECTLY OR INDIRECTLY, FINANCIAL SUPPORT
2 FROM FUNDS MANAGED OR DIRECTED BY AN INVESTIGATOR; AND

3 (4) DOES NOT HAVE ANY INVESTMENT OR OTHER FINANCIAL INTEREST
4 IN ANY BUSINESS ENTITY THAT:

5 (I) IS A SPONSOR OF THE RESEARCH; OR

6 (II) MAY BENEFIT DIRECTLY FROM THE OUTCOME OF THE
7 RESEARCH.

8 (G) "HEALTH CARE AGENT" MEANS A DISINTERESTED INDIVIDUAL
9 APPOINTED BY AN INDIVIDUAL PURSUANT TO THE HEALTH CARE DECISIONS ACT TO
10 MAKE A HEALTH CARE DECISION FOR THE INDIVIDUAL.

11 (H) "HEALTH CARE DECISIONS ACT" MEANS TITLE 5, SUBTITLE 6 OF THIS
12 ARTICLE.

13 (I) "INFORMED CONSENT" MEANS:

14 (1) THE VOLUNTARY AGREEMENT BY AN INDIVIDUAL TO PARTICIPATE
15 IN RESEARCH AFTER DISCLOSURE TO THE INDIVIDUAL OF ALL MATERIAL
16 INFORMATION AS DETERMINED BY AN IRB IN ACCORDANCE WITH THE COMMON
17 RULE; OR

18 (2) IF AN INDIVIDUAL IS A DECISIONALLY INCAPACITATED INDIVIDUAL,
19 THE VOLUNTARY AGREEMENT BY A LEGALLY AUTHORIZED REPRESENTATIVE FOR
20 THE DECISIONALLY INCAPACITATED INDIVIDUAL TO PARTICIPATE IN RESEARCH
21 AFTER DISCLOSURE TO THE LEGALLY AUTHORIZED REPRESENTATIVE OF ALL
22 RELEVANT INFORMATION AS DETERMINED BY AN IRB IN ACCORDANCE WITH THE
23 COMMON RULE AND THIS SUBTITLE.

24 (J) "INVESTIGATOR" MEANS A PERSON WHO CONDUCTS RESEARCH BY MEANS
25 OF:

26 (1) A PHYSICAL PROCEDURE BY WHICH DATA ARE GATHERED FROM A
27 LIVING INDIVIDUAL;

28 (2) MANIPULATION OF AN INDIVIDUAL OR THE ENVIRONMENT OF THE
29 INDIVIDUAL;

30 (3) COMMUNICATION OR INTERPERSONAL CONTACT BETWEEN THE
31 INVESTIGATOR AND AN INDIVIDUAL; OR

32 (4) COLLECTION OF INDIVIDUALLY IDENTIFIABLE PRIVATE
33 INFORMATION, INCLUDING INFORMATION THAT:

34 (I) CONCERNS BEHAVIOR OCCURRING IN A CONTEXT IN WHICH AN
35 INDIVIDUAL CAN REASONABLY EXPECT THAT NO OBSERVATION OR RECORDING IS
36 TAKING PLACE; OR

1 (II) HAS OTHERWISE BEEN PROVIDED BY AN INDIVIDUAL UNDER
2 CIRCUMSTANCES CAUSING THE INDIVIDUAL REASONABLY TO EXPECT THAT THE
3 INFORMATION WILL NOT BE MADE PUBLIC.

4 (K) "IRB" MEANS AN INSTITUTIONAL REVIEW BOARD WHOSE MEMBERSHIP
5 AND PROCESSES COMPLY WITH THE REQUIREMENTS OF THE COMMON RULE.

6 (L) "LEGALLY AUTHORIZED REPRESENTATIVE" MEANS A DISINTERESTED
7 INDIVIDUAL AUTHORIZED UNDER THIS SUBTITLE TO GIVE CONSENT TO
8 PARTICIPATION BY A DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH.

9 (M) "MEDICAL BEST INTEREST" MEANS THAT THE BURDEN TO THE
10 INDIVIDUAL RESULTING FROM PARTICIPATION IN RESEARCH IS DETERMINED BY A
11 LEGALLY AUTHORIZED REPRESENTATIVE TO BE ACCEPTABLE IN RELATION TO THE
12 POTENTIAL MEDICAL BENEFIT TO THE INDIVIDUAL RESULTING FROM
13 PARTICIPATION BY THE INDIVIDUAL IN RESEARCH, TAKING INTO ACCOUNT:

14 (1) THE EFFECT OF PARTICIPATION IN RESEARCH ON THE PHYSICAL,
15 EMOTIONAL, AND COGNITIVE FUNCTIONS OF THE INDIVIDUAL;

16 (2) THE DEGREE OF PHYSICAL PAIN OR DISCOMFORT, PSYCHOLOGICAL
17 DISTRESS, OR LOSS OF DIGNITY CAUSED TO THE INDIVIDUAL BY PARTICIPATION IN
18 RESEARCH;

19 (3) THE PROGNOSIS OF THE INDIVIDUAL;

20 (4) ANY RISK, SIDE EFFECT, AND BENEFIT OF PARTICIPATION IN
21 RESEARCH, COMPARED TO ANY RISK, SIDE EFFECT, AND BENEFIT OF STANDARD
22 TREATMENT; AND

23 (5) THE RELIGIOUS BELIEFS AND BASIC VALUES OF THE INDIVIDUAL,
24 TO THE EXTENT THAT THESE MAY ASSIST A LEGALLY AUTHORIZED
25 REPRESENTATIVE IN DETERMINING THE MEDICAL BEST INTEREST OF THE
26 INDIVIDUAL.

27 (N) "MEDICALLY RESPONSIBLE CLINICIAN" MEANS A LICENSED PHYSICIAN
28 OR INDIVIDUAL AUTHORIZED BY LAW TO ACT UNDER THE SUPERVISION OF A
29 PHYSICIAN WHO CARRIES OUT THE DUTIES STATED IN § 20-721 OF THIS SUBTITLE.

30 (O) (1) "MINIMAL RISK" MEANS THAT THE PROBABILITY AND MAGNITUDE
31 OF HARM OR DISCOMFORT ANTICIPATED IN RESEARCH, INCLUDING PSYCHOLOGICAL
32 HARM AND LOSS OF PRIVACY OR OTHER ASPECTS OF PERSONAL DIGNITY, ARE NOT
33 GREATER IN AND OF THEMSELVES THAN THOSE ORDINARILY ENCOUNTERED IN
34 DAILY LIFE OR DURING THE PERFORMANCE OF A ROUTINE PHYSICAL OR
35 PSYCHOLOGICAL EXAMINATION OR TEST.

36 (2) "MINIMAL RISK" INCLUDES A TYPE OF RESEARCH THAT IS
37 DESIGNATED AS "MINIMAL RISK" IN A REGULATION OF THE SECRETARY.

1 (P) (1) "MINOR INCREASE OVER MINIMAL RISK" MEANS THAT THE
2 PROBABILITY AND MAGNITUDE OF HARM OR DISCOMFORT ANTICIPATED IN
3 RESEARCH, INCLUDING PSYCHOLOGICAL HARM AND LOSS OF PRIVACY OR OTHER
4 ASPECTS OF PERSONAL DIGNITY, ARE ONLY SLIGHTLY GREATER IN AND OF
5 THEMSELVES THAN THOSE ORDINARILY ENCOUNTERED IN DAILY LIFE OR DURING
6 THE PERFORMANCE OF A ROUTINE PHYSICAL OR PSYCHOLOGICAL EXAMINATION OR
7 TEST.

8 (2) "MINOR INCREASE OVER MINIMAL RISK" INCLUDES A TYPE OF
9 RESEARCH THAT IS DESIGNATED AS "MINOR INCREASE OVER MINIMAL RISK" IN A
10 REGULATION OF THE SECRETARY.

11 (Q) "MONITOR" MEANS A DISINTERESTED INDIVIDUAL WHO IS DESIGNATED
12 BY AN IRB TO:

13 (1) MONITOR THE INFORMED CONSENT PROCESS WHEN A RESEARCH
14 AGENT IS CONSIDERING WHETHER TO GIVE INFORMED CONSENT TO PARTICIPATION
15 BY A DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH GOVERNED BY PART
16 VIII OF THIS SUBTITLE; OR

17 (2) PERFORM OTHER MONITORING DUTIES SPECIFIED BY THE IRB.

18 (R) "POTENTIALLY INCAPACITATING CONDITION" MEANS A MEDICAL
19 CONDITION THAT, AS DETERMINED BY AN IRB, IN ITS NORMAL COURSE RESULTS IN A
20 HIGHER RATE OF DECISIONAL INCAPACITY AMONG INDIVIDUALS WITH THE
21 CONDITION THAN AMONG OTHERWISE COMPARABLE INDIVIDUALS WITHOUT THE
22 CONDITION.

23 (S) "PROXY DECISION MAKER" MEANS A DISINTERESTED INDIVIDUAL WHO IS
24 DESIGNATED BY AN IRB TO CONSIDER WHETHER TO GIVE INFORMED CONSENT TO
25 PARTICIPATION BY A DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH
26 GOVERNED BY PART VI OF THIS SUBTITLE.

27 (T) "REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT" MEANS THAT, ON
28 THE BASIS OF SCIENTIFIC EVIDENCE, A REALISTIC POSSIBILITY EXISTS THAT THE
29 MEDICAL CONDITION OF AN INDIVIDUAL WOULD BE IMPROVED AS A DIRECT RESULT
30 OF PARTICIPATION IN RESEARCH, INCLUDING AMELIORATING SYMPTOMS OR
31 AVOIDING SIDE EFFECTS OF STANDARD THERAPY.

32 (U) "RESEARCH" MEANS A SYSTEMATIC INVESTIGATION INCLUDING
33 DEVELOPMENT, TESTING, AND EVALUATION, DESIGNED TO DEVELOP OR
34 CONTRIBUTE TO GENERALIZABLE KNOWLEDGE.

35 (V) "RESEARCH ADVANCE DIRECTIVE" MEANS AN ADVANCE DIRECTIVE MADE
36 IN ACCORDANCE WITH § 20-711 OF THIS SUBTITLE.

37 (W) "RESEARCH AGENT" MEANS A DISINTERESTED INDIVIDUAL WHO, UNDER
38 A RESEARCH ADVANCE DIRECTIVE, IS EXPRESSLY AUTHORIZED TO MAKE A
39 DECISION CONCERNING PARTICIPATION BY AN INDIVIDUAL IN RESEARCH.

1 (X) "RESEARCH PROTOCOL" MEANS A DETAILED, WRITTEN EXPLANATION BY
2 AN INVESTIGATOR OF THE OBJECTIVES, RATIONALE, AND DESIGN OF PARTICULAR
3 RESEARCH.

4 (Y) "SECRETARY" MEANS THE SECRETARY OF HEALTH AND MENTAL
5 HYGIENE.

6 (Z) (1) "SURROGATE" MEANS A DISINTERESTED INDIVIDUAL WHO IS
7 AUTHORIZED BY THE HEALTH CARE DECISIONS ACT TO MAKE A HEALTH CARE
8 DECISION FOR AN INDIVIDUAL.

9 (2) "SURROGATE" DOES NOT INCLUDE AN INDIVIDUAL WHO IS A
10 RESEARCH AGENT OR A HEALTH CARE AGENT.

11 20-702.

12 THE GENERAL ASSEMBLY FINDS THAT:

13 (1) ALL RESEARCH INVOLVING A HUMAN SUBJECT IN THIS STATE,
14 INCLUDING RESEARCH INVOLVING A DECISIONALLY INCAPACITATED INDIVIDUAL,
15 SHOULD BE CONDUCTED WITH THE UTMOST RESPECT FOR THE WELL-BEING AND
16 DIGNITY OF EACH RESEARCH SUBJECT;

17 (2) EXCEPT AS OTHERWISE SPECIFICALLY AUTHORIZED UNDER
18 FEDERAL OR STATE LAW, ALL RESEARCH INVOLVING A HUMAN SUBJECT IN THIS
19 STATE SHOULD BE CONDUCTED ONLY AFTER EACH SUBJECT PROVIDES INFORMED
20 CONSENT TO PARTICIPATION IN THE RESEARCH;

21 (3) RESEARCH SHOULD NEVER INVOLVE A DECISIONALLY
22 INCAPACITATED INDIVIDUAL AS A SUBJECT IF THE RESEARCH COULD BE DONE
23 WITH A SUBJECT WHO PROVIDES INFORMED CONSENT;

24 (4) RESEARCH INVOLVING A DECISIONALLY INCAPACITATED
25 INDIVIDUAL MAY BE ESSENTIAL UNDER SOME CIRCUMSTANCES IF SCIENCE IS TO
26 UNDERSTAND AND ULTIMATELY COMBAT DISEASES OF THE BRAIN, INCLUDING
27 ALZHEIMER'S DISEASE, SEVERE PSYCHIATRIC DISORDERS, SEVERE TRAUMA,
28 STROKE, OTHER CAUSES OF DECISIONAL INCAPACITY, AND THE MEDICAL PROBLEMS
29 THAT ARE ASSOCIATED WITH THESE CONDITIONS AND DISORDERS;

30 (5) A RESEARCHER SHOULD SEEK TO ENROLL A DECISIONALLY
31 INCAPACITATED INDIVIDUAL AS A RESEARCH SUBJECT ONLY IF THE RESEARCH IS
32 EXPECTED TO YIELD GENERALIZABLE KNOWLEDGE IMPORTANT TO THE
33 UNDERSTANDING OR AMELIORATION OF THE DISORDER OR CONDITION OF THE
34 SUBJECT AND RELATED MEDICAL PROBLEMS, AND THE KNOWLEDGE CAN NOT BE
35 OBTAINED WITHOUT PARTICIPATION OF THE SUBJECT; AND

36 (6) THE INFORMED CONSENT PROCESS PRECEDING RESEARCH
37 PARTICIPATION SHOULD CONVEY ALL MATERIAL INFORMATION ABOUT THE
38 RESEARCH IN A CLEAR AND UNDERSTANDABLE WAY AND EMPHASIZE, WHEN

1 APPROPRIATE, THAT THE RESEARCH IS NOT EXPECTED TO PROVIDE A DIRECT
2 MEDICAL BENEFIT TO THE RESEARCH SUBJECT.

3 20-703.

4 (A) EXCEPT AS PROVIDED IN SUBSECTION (B) OF THIS SECTION:

5 (1) ALL RESEARCH IN THIS STATE INVOLVING A DECISIONALLY
6 INCAPACITATED INDIVIDUAL SHALL COMPLY WITH THIS SUBTITLE; AND

7 (2) RESEARCH INVOLVING A DECISIONALLY INCAPACITATED
8 INDIVIDUAL THAT IS NOT EXPRESSLY AUTHORIZED IN THIS SUBTITLE IS
9 PROHIBITED.

10 (B) THIS SUBTITLE DOES NOT APPLY IF RESEARCH:

11 (1) IS EXEMPT UNDER 45 C.F.R. § 46.101(B) FROM THE REQUIREMENTS OF
12 THE COMMON RULE;

13 (2) CONCERNS TREATMENT FOR A LIFE-THREATENING EMERGENCY
14 AND IS CONDUCTED IN ACCORDANCE WITH A REGULATION OF THE UNITED STATES
15 FOOD AND DRUG ADMINISTRATION OR A WAIVER OF INFORMED CONSENT BY THE
16 UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; OR

17 (3) (I) IS LIMITED TO THE STUDY OF EXISTING DATA, DOCUMENTS,
18 RECORDS, PATHOLOGICAL SPECIMENS, OR DIAGNOSTIC SPECIMENS;

19 (II) WILL BE CONDUCTED UNDER PROCEDURES APPROVED BY AN
20 IRB SUFFICIENT TO SAFEGUARD THE PRIVACY OF THE INDIVIDUAL WHOSE DATA,
21 DOCUMENTS, OR SPECIMENS ARE STUDIED AND ANY OTHER IDENTIFIABLE
22 INDIVIDUAL ABOUT WHOM PERSONAL INFORMATION MIGHT BE LEARNED AS A
23 RESULT OF THE RESEARCH; AND

24 (III) IS GRANTED A WAIVER OF INFORMED CONSENT BY THE IRB
25 UNDER 45 C.F.R. § 46.116(D).

26 (C) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION, AND
27 SUBJECT TO § 20-704(A) AND PART II OF THIS SUBTITLE, NOTHING IN THIS SUBTITLE
28 AFFECTS RESEARCH THAT INVOLVES AN INDIVIDUAL WHO GIVES INFORMED
29 CONSENT TO BECOME A SUBJECT OF THE RESEARCH.

30 (2) IF AN INDIVIDUAL WHO GIVES INFORMED CONSENT FOR
31 PARTICIPATION IN RESEARCH BECOMES A DECISIONALLY INCAPACITATED
32 INDIVIDUAL DURING THE COURSE OF THE RESEARCH, CONTINUED PARTICIPATION
33 BY THE INDIVIDUAL IN THE RESEARCH IS SUBJECT TO § 20-728(B) OF THIS SUBTITLE.

34 (D) NOTHING IN THIS SUBTITLE AUTHORIZES A SURROGATE OR A PROXY
35 DECISION MAKER TO CONSENT TO:

1 (1) THE ADMISSION OF A DECISIONALLY INCAPACITATED INDIVIDUAL
2 TO A MENTAL HEALTH FACILITY; OR

3 (2) A BEHAVIOR MODIFICATION PROGRAM INVOLVING AVERSIVE
4 STIMULI THAT ARE PAINFUL OR INVASIVE.

5 (E) NOTHING IN THIS SUBTITLE AUTHORIZES AN INVESTIGATOR:

6 (1) TO INVOLVE AN INDIVIDUAL IN AN ACTION RELATED TO RESEARCH
7 IF THE INVESTIGATOR IS AWARE THAT THE INDIVIDUAL HAS EXPRESSED
8 DISAGREEMENT WITH THE ACTION; OR

9 (2) TO COMPEL A DECISIONALLY INCAPACITATED INDIVIDUAL TO
10 PERFORM AN ACTION RELATED TO THE RESEARCH IF THE INDIVIDUAL REFUSES TO
11 TAKE THE ACTION AFTER BEING ASKED TO DO SO.

12 (F) EXCEPT AS PROVIDED IN § 20-727(B) OF THIS SUBTITLE, THIS SUBTITLE
13 MAY NOT AFFECT THE AUTHORITY OF A COURT OR A GUARDIAN OF THE PERSON
14 APPOINTED UNDER TITLE 13, SUBTITLE 7 OF THE ESTATES AND TRUSTS ARTICLE.

15 20-704.

16 (A) AN INVESTIGATOR WHO PLANS TO RECRUIT A POTENTIAL RESEARCH
17 SUBJECT FROM AMONG INDIVIDUALS WITH A POTENTIALLY INCAPACITATING
18 CONDITION SHALL COMPLY WITH ALL REQUIREMENTS APPLICABLE TO AN
19 INVESTIGATOR UNDER THE COMMON RULE AND PART II OF THIS SUBTITLE.

20 (B) AN INVESTIGATOR WHO CONDUCTS RESEARCH INVOLVING A
21 DECISIONALLY INCAPACITATED INDIVIDUAL SHALL COMPLY WITH ALL
22 REQUIREMENTS APPLICABLE TO AN INVESTIGATOR UNDER THE COMMON RULE AND
23 THIS SUBTITLE.

24 (C) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION, AN
25 INVESTIGATOR MAY INVOLVE A DECISIONALLY INCAPACITATED INDIVIDUAL AS A
26 RESEARCH SUBJECT ONLY IN RESEARCH THAT RELATES DIRECTLY TO:

27 (I) THE CONDITION THAT HAS RESULTED IN THE DECISIONAL
28 INCAPACITY OF THAT INDIVIDUAL;

29 (II) A DEMONSTRATED OR REASONABLY PREDICTED
30 RELATIONSHIP BETWEEN THAT CONDITION AND ANY OTHER MEDICAL CONDITION
31 OF THE DECISIONALLY INCAPACITATED INDIVIDUAL; OR

32 (III) AN ASSESSMENT OF THE EFFICACY OF AN INTERVENTION
33 ALREADY USED IN CLINICAL PRACTICE TO TREAT A CONDITION OR RELATIONSHIP
34 DESCRIBED IN SUBPARAGRAPH (I) OR (II) OF THIS PARAGRAPH.

35 (2) IF RESEARCH DOES NOT MEET THE CRITERIA SPECIFIED IN
36 PARAGRAPH (1) OF THIS SUBSECTION, AN INVESTIGATOR MAY INVOLVE A
37 DECISIONALLY INCAPACITATED INDIVIDUAL AS A RESEARCH SUBJECT ONLY IF:

1 (I) THE RESEARCH, AS APPROVED BY AN IRB, HOLDS OUT A
2 REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO THE DECISIONALLY
3 INCAPACITATED INDIVIDUAL;

4 (II) THE INVESTIGATOR DID NOT DESIGN THE RESEARCH TO
5 INVOLVE A DECISIONALLY INCAPACITATED INDIVIDUAL;

6 (III) THE DECISIONALLY INCAPACITATED INDIVIDUAL MEETS ALL
7 APPLICABLE CRITERIA FOR PARTICIPATION IN THE RESEARCH;

8 (IV) IN ACCORDANCE WITH PART VI OF THIS SUBTITLE, THE
9 INVESTIGATOR OBTAINS THE INFORMED CONSENT OF A LEGALLY AUTHORIZED
10 REPRESENTATIVE OF THE DECISIONALLY INCAPACITATED INDIVIDUAL OR OF A
11 COURT OR GUARDIAN OF THE DECISIONALLY INCAPACITATED INDIVIDUAL; AND

12 (V) THE INVESTIGATOR PROMPTLY NOTIFIES THE IRB THAT THE
13 DECISIONALLY INCAPACITATED INDIVIDUAL IS PARTICIPATING IN THE RESEARCH.

14 20-705. RESERVED.

15 20-706. RESERVED.

16 PART II. CAPACITY ASSESSMENT - INDIVIDUALS WITH POTENTIALLY
17 INCAPACITATING CONDITIONS.

18 20-707.

19 (A) THIS SECTION APPLIES IF AN INVESTIGATOR INTENDS TO RECRUIT A
20 RESEARCH SUBJECT AMONG INDIVIDUALS WITH A POTENTIALLY INCAPACITATING
21 CONDITION, WHETHER OR NOT PARTICIPATION IN RESEARCH WILL BE BASED ON
22 THE INFORMED CONSENT OF THE INDIVIDUALS OR OF THE LEGALLY AUTHORIZED
23 REPRESENTATIVES OF THE INDIVIDUALS.

24 (B) THE INVESTIGATOR SHALL:

25 (1) AS PART OF THE RESEARCH PROTOCOL, DESCRIBE TO THE IRB:

26 (I) THE PROCEDURE THAT THE INVESTIGATOR PLANS TO USE TO
27 ASSESS WHETHER OR NOT THE INDIVIDUAL IS ABLE TO GIVE INFORMED CONSENT
28 TO PARTICIPATION IN RESEARCH, INCLUDING THE PROCEDURE FOR DOCUMENTING
29 THE ASSESSMENT;

30 (II) THE REASONABLE ACCOMMODATION THAT THE INVESTIGATOR
31 PLANS TO PROVIDE SO AS TO ENABLE AS MANY INDIVIDUALS AS POSSIBLE TO
32 DECIDE PERSONALLY ABOUT PARTICIPATION IN RESEARCH;

33 (III) ANY PROCEDURE THAT THE INVESTIGATOR PLANS TO USE TO
34 REASSESS THE CAPACITY OF AN INDIVIDUAL DURING THE COURSE OF THE
35 RESEARCH; AND

1 (IV) THE STEPS THAT THE INVESTIGATOR INTENDS TO TAKE IF AN
2 INDIVIDUAL WHO GAVE INFORMED CONSENT BECOMES DECISIONALLY
3 INCAPACITATED DURING THE COURSE OF THE RESEARCH, INCLUDING THE
4 PROCEDURE FOR NOTIFYING THE LEGALLY AUTHORIZED REPRESENTATIVE OF THE
5 INDIVIDUAL; AND

6 (2) AS PART OF AN ANNUAL REVIEW OR MORE FREQUENTLY IF
7 DIRECTED BY THE IRB, INFORM THE IRB WHETHER ANY INDIVIDUAL WHO INITIALLY
8 WAS DETERMINED BY THE INVESTIGATOR TO BE ABLE TO GIVE INFORMED CONSENT
9 BECAME DECISIONALLY INCAPACITATED DURING THE COURSE OF THE RESEARCH
10 AND, IF SO, WHAT STEPS THE INVESTIGATOR TOOK CONCERNING THE CONTINUED
11 PARTICIPATION OF THAT INDIVIDUAL IN THE RESEARCH.

12 (C) AN INDIVIDUAL WHO IS ABLE TO COMMUNICATE BY MEANS OTHER THAN
13 SPEECH MAY NOT BE CONSIDERED INCAPABLE OF GIVING INFORMED CONSENT
14 SOLELY BY REASON OF THE INABILITY TO SPEAK.

15 20-708.

16 AFTER AN INVESTIGATOR PROVIDES AN IRB WITH THE DESCRIPTION REQUIRED
17 BY § 20-707(B)(1) OF THIS SUBTITLE, THE IRB SHALL:

18 (1) CONSIDER WHETHER TO APPROVE, AS REASONABLE UNDER THE
19 CIRCUMSTANCES, THE PROCEDURE THE INVESTIGATOR INTENDS TO USE;

20 (2) IN LIGHT OF THE POTENTIALLY INCAPACITATING CONDITION,
21 CONSIDER WHETHER THE RISK TO WHICH A RESEARCH SUBJECT WOULD BE
22 EXPOSED, AND ANY OTHER RELEVANT CIRCUMSTANCE, REQUIRES THAT A MONITOR
23 CONDUCT OR OBSERVE THE PROCEDURE; AND

24 (3) DOCUMENT ITS DECISION IN ITS MINUTES.

25 20-709. RESERVED.

26 20-710. RESERVED.

27 PART III. RESEARCH ADVANCE DIRECTIVES.

28 20-711.

29 (A) AN INDIVIDUAL WHO HAS THE CAPACITY TO EXECUTE AN ADVANCE
30 DIRECTIVE FOR HEALTH CARE UNDER THE HEALTH CARE DECISIONS ACT MAY
31 EXECUTE A RESEARCH ADVANCE DIRECTIVE.

32 (B) A RESEARCH ADVANCE DIRECTIVE SHALL BE EXECUTED AND WITNESSED
33 IN ACCORDANCE WITH § 5-602 OF THIS ARTICLE.

34 (C) A RESEARCH ADVANCE DIRECTIVE IS NOT EFFECTIVE UNLESS IT:

35 (1) DESIGNATES A RESEARCH AGENT; AND

1 (2) DESCRIBES, BY REFERENCE TO A PARTICULAR MEDICAL CONDITION,
2 LEVEL OF RISK, OR OTHER PERTINENT FACTORS, THE RESEARCH IN WHICH AN
3 INDIVIDUAL IS WILLING TO PARTICIPATE IF THE INDIVIDUAL IS OR BECOMES
4 UNABLE TO GIVE INFORMED CONSENT TO PARTICIPATION IN THE RESEARCH.

5 (D) AFTER CONSULTATION WITH INTERESTED PERSONS, THE OFFICE OF THE
6 ATTORNEY GENERAL SHALL PREPARE AND DISTRIBUTE A MODEL FORM OF A
7 RESEARCH ADVANCE DIRECTIVE, THE USE OF WHICH SHALL BE OPTIONAL.

8 (E) (1) THIS SUBSECTION DOES NOT PROHIBIT AN INVESTIGATOR, IN
9 ACCORDANCE WITH THIS SUBTITLE, FROM REQUESTING AN INDIVIDUAL TO
10 EXECUTE A RESEARCH ADVANCE DIRECTIVE.

11 (2) A HEALTH CARE FACILITY MAY NOT REQUEST, AS A ROUTINE
12 MATTER, THAT A PATIENT EXECUTE A RESEARCH ADVANCE DIRECTIVE.

13 20-712.

14 (A) IF AN INVESTIGATOR INTENDS TO REQUEST THAT AN INDIVIDUAL WITH A
15 POTENTIALLY INCAPACITATING CONDITION EXECUTE A RESEARCH ADVANCE
16 DIRECTIVE, THE INVESTIGATOR SHALL, AS PART OF THE RESEARCH PROTOCOL,
17 DESCRIBE TO THE IRB THE PROCEDURE THAT THE INVESTIGATOR INTENDS TO USE
18 TO ASSESS WHETHER THE INDIVIDUAL HAS THE CAPACITY TO EXECUTE A RESEARCH
19 ADVANCE DIRECTIVE, INCLUDING THE PROCEDURE FOR DOCUMENTING THE
20 ASSESSMENT.

21 (B) THE IRB SHALL:

22 (1) CONSIDER WHETHER TO APPROVE, AS REASONABLE UNDER THE
23 CIRCUMSTANCES, THE PROCEDURE INTENDED TO BE USED BY THE INVESTIGATOR;

24 (2) IN LIGHT OF THE POTENTIALLY INCAPACITATING CONDITION,
25 CONSIDER WHETHER THE RISK TO WHICH A RESEARCH SUBJECT WOULD BE
26 EXPOSED, AND ANY OTHER RELEVANT CIRCUMSTANCE, REQUIRES THAT A MONITOR
27 CONDUCT OR OBSERVE THE PROCEDURE; AND

28 (3) DOCUMENT ITS DECISION IN ITS MINUTES.

29 20-713.

30 (A) EXCEPT AS PROVIDED IN SUBSECTION (B) OF THIS SECTION, A RESEARCH
31 ADVANCE DIRECTIVE MAY BE GIVEN EFFECT IN ACCORDANCE WITH ITS TERMS.

32 (B) (1) THIS SUBSECTION APPLIES TO A RESEARCH ADVANCE DIRECTIVE
33 THAT AN INDIVIDUAL EXECUTES AFTER AN INVESTIGATOR:

34 (I) APPROACHES THE INDIVIDUAL ABOUT PARTICIPATION IN
35 RESEARCH; AND

1 (II) DETERMINES THAT, ALTHOUGH THE INDIVIDUAL LACKS THE
2 CAPACITY TO GIVE INFORMED CONSENT TO PARTICIPATION IN RESEARCH, THE
3 INDIVIDUAL NEVERTHELESS RETAINS THE CAPACITY TO EXECUTE A RESEARCH
4 ADVANCE DIRECTIVE.

5 (2) UNLESS THE PROCEDURE SPECIFIED IN PARAGRAPH (3) OF THIS
6 SUBSECTION IS FOLLOWED, A RESEARCH ADVANCE DIRECTIVE EXECUTED UNDER
7 THE CIRCUMSTANCES SPECIFIED IN PARAGRAPH (1) OF THIS SUBSECTION MAY BE
8 APPLIED ONLY TO RESEARCH THAT, AS DETERMINED BY AN IRB:

9 (I) PRESENTS A REASONABLE PROSPECT OF DIRECT MEDICAL
10 BENEFIT TO A RESEARCH PARTICIPANT; OR

11 (II) PRESENTS NO MORE THAN A MINIMAL RISK TO A RESEARCH
12 PARTICIPANT.

13 (3) SUBJECT TO THE TERMS OF A RESEARCH ADVANCE DIRECTIVE, THE
14 RESEARCH ADVANCE DIRECTIVE DESCRIBED IN THIS SUBSECTION MAY BE GIVEN
15 EFFECT IN OTHER RESEARCH IF THE RESEARCH ADVANCE DIRECTIVE IS EXECUTED
16 IN THE PRESENCE OF A MONITOR WHO DETERMINES THAT THE INDIVIDUAL:

17 (I) UNDERSTANDS THE NATURE AND EXTENT OF THE RESEARCH
18 ADVANCE DIRECTIVE AND THE PROBABLE CONSEQUENCES OF EXECUTING IT; AND

19 (II) INTENDS TO AUTHORIZE THE RESEARCH AGENT TO CONSENT
20 TO THE TYPE OF RESEARCH DESCRIBED IN THE RESEARCH ADVANCE DIRECTIVE.

21 20-714. RESERVED.

22 20-715. RESERVED.

23 PART IV. RESEARCH INVOLVING DECISIONALLY INCAPACITATED INDIVIDUALS -
24 INVESTIGATOR AND IRB RESPONSIBILITIES.

25 20-716.

26 IF AN INVESTIGATOR PLANS TO INVOLVE A DECISIONALLY INCAPACITATED
27 INDIVIDUAL AS A RESEARCH SUBJECT, THE INVESTIGATOR SHALL, AS PART OF THE
28 RESEARCH PROTOCOL:

29 (1) DESCRIBE TO AN IRB THE CATEGORY OF DECISIONALLY
30 INCAPACITATED INDIVIDUALS WHO WILL BE ELIGIBLE TO BE INVOLVED IN THE
31 RESEARCH;

32 (2) EXPLAIN TO THE IRB WHY THE PROPOSED RESEARCH CANNOT BE
33 CONDUCTED WITHOUT THE INVOLVEMENT OF A DECISIONALLY INCAPACITATED
34 INDIVIDUAL;

1 (3) PROVIDE THE IRB WITH THE RESULTS OF ANY PRIOR REVIEW OF THE
2 SCIENTIFIC MERITS OF THE PROPOSED RESEARCH OR EXPLAIN TO THE IRB WHY THE
3 SCIENTIFIC MERITS OF THE PROPOSED RESEARCH HAVE NOT BEEN REVIEWED;

4 (4) INFORM THE IRB WHETHER ANY OTHER IRB HAS FAILED TO
5 APPROVE THE RESEARCH OR SUBSTANTIALLY EQUIVALENT RESEARCH PROPOSED
6 BY THE INVESTIGATOR;

7 (5) INFORM THE IRB WHETHER ANY INVESTIGATOR INVOLVED IN THE
8 RESEARCH HAS EVER BEEN:

9 (I) FOUND BY AN AGENCY OF THE UNITED STATES, THIS STATE, OR
10 ANOTHER STATE TO HAVE VIOLATED ANY FEDERAL OR STATE STATUTE OR
11 REGULATION OR IRB REQUIREMENT PROTECTING THE RIGHTS AND WELFARE OF A
12 RESEARCH SUBJECT; OR

13 (II) INVOLVED IN RESEARCH FOR WHICH IRB APPROVAL WAS
14 WITHDRAWN BECAUSE OF NONCOMPLIANCE WITH ANY FEDERAL OR STATE
15 STATUTE OR REGULATION OR IRB REQUIREMENT PROTECTING THE RIGHTS AND
16 WELFARE OF A RESEARCH SUBJECT;

17 (6) DESCRIBE TO THE IRB THE PROCEDURE THAT THE INVESTIGATOR
18 INTENDS TO FOLLOW TO ACHIEVE COMPLIANCE WITH THE REQUIREMENTS OF THIS
19 SUBTITLE;

20 (7) DESCRIBE TO THE IRB THE PROCEDURE BY WHICH THE HEALTH AND
21 SAFETY OF A RESEARCH SUBJECT IS TO BE MONITORED DURING THE COURSE OF
22 THE RESEARCH, INCLUDING:

23 (I) WHETHER A DISINTERESTED, EXPERT BOARD OR COMMITTEE
24 WILL REVIEW INTERIM DATA RESULTING FROM THE RESEARCH AND EVALUATE THE
25 DATA IN TERMS OF THE SAFETY OF A RESEARCH SUBJECT; AND

26 (II) WHETHER THE ATTENDING PHYSICIAN OF A RESEARCH
27 SUBJECT IS TO BE CONSULTED ABOUT THE POTENTIAL EFFECT OF THE RESEARCH
28 ON THE RESEARCH SUBJECT AND, IF NOT, HOW PROPER COORDINATION WITH THE
29 CLINICAL CARE OF THE SUBJECT IS TO BE ACHIEVED;

30 (8) DESCRIBE TO THE IRB:

31 (I) HOW A LEGALLY AUTHORIZED REPRESENTATIVE MAY
32 OBSERVE THE RESEARCH OR OTHERWISE LEARN ABOUT THE EXPERIENCE OF A
33 DECISIONALLY INCAPACITATED INDIVIDUAL IN THE RESEARCH;

34 (II) WHETHER CONSENT FOR FURTHER PARTICIPATION IN
35 RESEARCH WILL BE SOUGHT FROM A LEGALLY AUTHORIZED REPRESENTATIVE AT
36 ANY POINT DURING THE RESEARCH; AND

1 (III) WHAT PROCEDURE IS TO BE USED FOR PERIODIC
2 CONFIRMATION THAT THE INDIVIDUAL REMAINS WILLING TO PARTICIPATE IN THE
3 RESEARCH;

4 (9) IF THE DESIGN OF THE RESEARCH INCLUDES THE USE OF A
5 PLACEBO CONTROL, DESCRIBE TO THE IRB:

6 (I) WHY A CONTROL PROCEDURE OTHER THAN PLACEBO CONTROL
7 COULD NOT BE USED;

8 (II) IF A STANDARD THERAPY EXISTS, WHY THE USE OF A PLACEBO
9 CONTROL IS CONSISTENT WITH THE WELL-BEING OF A SUBJECT IN THE PLACEBO
10 CONTROL ARM; AND

11 (III) WHETHER A RESEARCH SUBJECT INITIALLY RANDOMIZED TO
12 THE PLACEBO CONTROL ARM CAN RECEIVE A DRUG UNDER STUDY AT ANY TIME
13 DURING OR AFTER THE RESEARCH;

14 (10) IF THE DESIGN OF THE RESEARCH REQUIRES THAT NEITHER THE
15 INVESTIGATOR NOR A LEGALLY AUTHORIZED REPRESENTATIVE KNOW WHETHER A
16 SPECIFIC RESEARCH SUBJECT IS RECEIVING A DRUG UNDER STUDY OR SOME OTHER
17 SUBSTANCE, DESCRIBE TO THE IRB THE PROCEDURE FOR DETERMINING THAT
18 INFORMATION IF IT BECOMES NECESSARY FOR THE CLINICAL CARE OF A RESEARCH
19 SUBJECT; AND

20 (11) IF THE RESEARCH PROTOCOL INVOLVES USE OF A SUBSTANCE OR
21 PROCEDURE DESIGNED TO PROVOKE OR AGGRAVATE A SYMPTOM OF A MEDICAL
22 CONDITION, EXPLAIN TO THE IRB WHY THE SUBSTANCE OR PROCEDURE IS
23 CONSISTENT WITH THE WELL-BEING OF A RESEARCH SUBJECT.

24 20-717.

25 (A) IN DECIDING WHETHER TO APPROVE RESEARCH IN WHICH AN
26 INVESTIGATOR PLANS TO INVOLVE A DECISIONALLY INCAPACITATED INDIVIDUAL,
27 AN IRB SHALL:

28 (1) CONSIDER WHETHER ADDITIONAL SAFEGUARDS, BEYOND THOSE
29 GENERALLY REQUIRED BY THE COMMON RULE, SHOULD BE ADOPTED TO PROTECT
30 THE RIGHTS AND WELFARE OF THE DECISIONALLY INCAPACITATED INDIVIDUAL
31 WHO WILL BE A RESEARCH SUBJECT;

32 (2) CONSIDER WHETHER, IN LIGHT OF THE RISK PRESENTED BY
33 PARTICIPATION IN RESEARCH, TO REQUIRE THAT A MONITOR PARTICIPATE IN OR
34 OBSERVE THE INFORMED CONSENT PROCESS REQUIRED BY § 20-724 OF THIS
35 SUBTITLE;

36 (3) REVIEW THE RESEARCH PROTOCOL TO DETERMINE THAT THE
37 PROPOSED PROCEDURE DOES NOT UNNECESSARILY EXPOSE A DECISIONALLY
38 INCAPACITATED INDIVIDUAL TO RISK, ESPECIALLY IF THE RESEARCH PROTOCOL
39 INCLUDES THE USE OF A PLACEBO CONTROL OR INVOLVES THE USE OF A

1 SUBSTANCE OR PROCEDURE DESIGNED TO PROVOKE OR AGGRAVATE THE SYMPTOM
2 OF A MEDICAL CONDITION; AND

3 (4) VERIFY THAT THE INVESTIGATOR HAS PROVIDED THE IRB WITH THE
4 INFORMATION REQUIRED BY § 20-716 OF THIS SUBTITLE.

5 (B) (1) AN IRB MAY DESIGNATE ONE OR MORE PROXY DECISION MAKERS,
6 MONITORS, AND MEDICALLY RESPONSIBLE CLINICIANS FOR RESEARCH CONDUCTED
7 IN AN INSTITUTION SERVED BY THE IRB.

8 (2) (I) EXCEPT AS PROVIDED IN SUBPARAGRAPHS (II) AND (III) OF THIS
9 PARAGRAPH, AN IRB MAY ONLY DESIGNATE A DISINTERESTED INDIVIDUAL AS A
10 PROXY DECISION MAKER, MONITOR, OR MEDICALLY RESPONSIBLE CLINICIAN.

11 (II) IN EXCEPTIONAL CIRCUMSTANCES DOCUMENTED IN THE
12 MINUTES OF AN IRB, THE IRB MAY DESIGNATE AS A PROXY DECISION MAKER OR
13 MONITOR AN INDIVIDUAL WHO DOES NOT MEET THE EMPLOYMENT RESTRICTION
14 SPECIFIED IN § 20-701(F)(2) OF THIS SUBTITLE BUT WHO IS OTHERWISE A
15 DISINTERESTED INDIVIDUAL AND IS EMPLOYED IN A PART OF AN INSTITUTION,
16 CORPORATION, HOSPITAL, OR HEALTH CARE FACILITY THAT IS ORGANIZATIONALLY
17 DISTINCT FROM THAT OF THE INVESTIGATORS.

18 (III) AN IRB MAY DESIGNATE AS A MEDICALLY RESPONSIBLE
19 CLINICIAN AN INDIVIDUAL WHO DOES NOT MEET THE EMPLOYMENT RESTRICTION
20 IN § 20-701(F)(2) OF THIS SUBTITLE BUT WHO IS OTHERWISE A DISINTERESTED
21 INDIVIDUAL AND IS EMPLOYED IN A PART OF AN INSTITUTION, CORPORATION,
22 HOSPITAL, OR HEALTH CARE FACILITY THAT IS ORGANIZATIONALLY DISTINCT FROM
23 THAT OF THE INVESTIGATORS.

24 (C) IF AN IRB LEARNS THAT AN INVESTIGATOR PARTICIPATING IN RESEARCH
25 IN WHICH A DECISIONALLY INCAPACITATED INDIVIDUAL IS INTENDED TO BE
26 INVOLVED HAS EVER BEEN FOUND BY AN AGENCY OF THE UNITED STATES, THIS
27 STATE, OR ANOTHER STATE TO HAVE VIOLATED ANY FEDERAL OR STATE STATUTE
28 OR REGULATION OR IRB REQUIREMENT PROTECTING THE RIGHTS AND WELFARE OF
29 A RESEARCH SUBJECT, THE IRB SHALL:

30 (1) DISAPPROVE THE CONDUCT OF THE RESEARCH; OR

31 (2) IF IT APPROVES THE CONDUCT OF THE RESEARCH:

32 (I) IMPLEMENT APPROPRIATE MEASURES FOR STRICT SCRUTINY
33 OF THE CONDUCT OF THE RESEARCH; AND

34 (II) PROVIDE THE SECRETARY AND THE ATTORNEY GENERAL WITH
35 THE INFORMATION AVAILABLE TO THE IRB CONCERNING THE VIOLATION AND THE
36 ACTION TAKEN BY THE IRB UNDER PARAGRAPH (1) OF THIS SUBSECTION.

1 20-718.

2 (A) (1) IF AN INVESTIGATOR SEEKS APPROVAL FOR RESEARCH IN WHICH A
3 DECISIONALLY INCAPACITATED INDIVIDUAL IS TO BE INVOLVED, AN IRB SHALL
4 DETERMINE AND STATE IN ITS MINUTES WHETHER THE RESEARCH PROTOCOL
5 PRESENTS A REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO THE
6 DECISIONALLY INCAPACITATED INDIVIDUAL.

7 (2) IN CONSIDERING WHETHER THE RESEARCH PROTOCOL PRESENTS A
8 REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO A DECISIONALLY
9 INCAPACITATED INDIVIDUAL, AN IRB SHALL TAKE INTO ACCOUNT THE RELEVANT
10 SCIENTIFIC EVIDENCE AVAILABLE TO IT CONCERNING THE NATURE AND
11 LIKELIHOOD OF A DIRECT MEDICAL BENEFIT.

12 (3) IF THE RESEARCH PROTOCOL INVOLVES THE USE OF A PLACEBO
13 CONTROL, THE IRB SHALL TAKE INTO ACCOUNT WHETHER A DECISIONALLY
14 INCAPACITATED INDIVIDUAL INITIALLY RANDOMIZED TO THE PLACEBO CONTROL
15 ARM CAN RECEIVE THE DRUG UNDER STUDY AT ANY TIME DURING OR AFTER THE
16 RESEARCH.

17 (4) IF THE RESEARCH PROTOCOL PRESENTS A REASONABLE PROSPECT
18 OF DIRECT MEDICAL BENEFIT TO A DECISIONALLY INCAPACITATED INDIVIDUAL,
19 THE IRB SHALL ENSURE THAT WRITTEN MATERIALS:

20 (I) ARE MADE AVAILABLE TO A LEGALLY AUTHORIZED
21 REPRESENTATIVE AS PART OF THE INFORMED CONSENT PROCESS;

22 (II) EMPHASIZE THAT THE PROCEDURE INVOLVES RESEARCH, NOT
23 STANDARD THERAPY; AND

24 (III) DESCRIBE FAIRLY THE RISKS AND BENEFITS OF
25 PARTICIPATION IN RESEARCH, INCLUDING THE EXTENT TO WHICH THE RESEARCH
26 ALTERS THE PROBABILITY OR MAGNITUDE OF HARM OR DISCOMFORT THAT A
27 DECISIONALLY INCAPACITATED INDIVIDUAL COULD BE EXPECTED TO EXPERIENCE
28 IF THE DECISIONALLY INCAPACITATED INDIVIDUAL DID NOT PARTICIPATE IN THE
29 RESEARCH.

30 (B) (1) THE IRB SHALL DETERMINE AND STATE IN ITS MINUTES WHETHER
31 THE RESEARCH PROTOCOL PRESENTS TO A DECISIONALLY INCAPACITATED
32 INDIVIDUAL A LEVEL OF RISK THAT IS:

33 (I) A MINIMAL RISK;

34 (II) A MINOR INCREASE OVER A MINIMAL RISK; OR

35 (III) MORE THAN A MINOR INCREASE OVER A MINIMAL RISK.

36 (2) IN CONSIDERING WHETHER THE RESEARCH PROTOCOL PRESENTS A
37 MINIMAL RISK, THE IRB MAY TAKE INTO ACCOUNT WHETHER THE RESEARCH

1 INVOLVES A PROCEDURE THAT THE UNITED STATES DEPARTMENT OF HEALTH AND
2 HUMAN SERVICES HAS IDENTIFIED AS SUITABLE FOR EXPEDITED IRB REVIEW.

3 (3) IN DETERMINING THE LEVEL OF RISK OF THE RESEARCH, THE IRB
4 SHALL CONSIDER WHETHER THE CHARACTERISTICS OF A DECISIONALLY
5 INCAPACITATED INDIVIDUAL WOULD RESULT IN A GREATER RISK TO THE
6 DECISIONALLY INCAPACITATED INDIVIDUAL THAN TO AN INDIVIDUAL DRAWN FROM
7 THE GENERAL POPULATION.

8 (4) AN IRB SHALL DETERMINE THAT A RESEARCH PROTOCOL PRESENTS
9 MORE THAN A MINOR INCREASE OVER A MINIMAL RISK IF, AS A RESULT OF
10 PARTICIPATION IN RESEARCH, A DECISIONALLY INCAPACITATED INDIVIDUAL
11 WOULD BE EXPOSED TO MORE THAN A REMOTE POSSIBILITY OF:

12 (I) SUBSTANTIAL OR PROLONGED PAIN, DISCOMFORT, OR
13 DISTRESS; OR

14 (II) CLINICALLY SIGNIFICANT DETERIORATION OF A MEDICAL
15 CONDITION.

16 20-719.

17 (A) AN INVESTIGATOR MAY NOT INVOLVE A DECISIONALLY INCAPACITATED
18 INDIVIDUAL IN RESEARCH UNLESS:

19 (1) THE RESEARCH PROTOCOL HAS BEEN APPROVED BY AN IRB; AND

20 (2) THE INVESTIGATOR CONDUCTS THE RESEARCH IN CONFORMITY
21 WITH ALL CONDITIONS IMPOSED BY THE IRB IN CONNECTION WITH ITS APPROVAL.

22 (B) (1) THIS SUBSECTION APPLIES IF A DECISIONALLY INCAPACITATED
23 INDIVIDUAL IS INVOLVED IN RESEARCH THAT, AS DETERMINED BY AN IRB,
24 PRESENTS A REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO THE
25 DECISIONALLY INCAPACITATED INDIVIDUAL.

26 (2) IF THE INVESTIGATOR DETERMINES THAT PARTICIPATION IN
27 RESEARCH NO LONGER PRESENTS A REASONABLE PROSPECT OF DIRECT MEDICAL
28 BENEFIT TO A DECISIONALLY INCAPACITATED INDIVIDUAL, THE INVESTIGATOR
29 SHALL:

30 (I) ADVISE THE LEGALLY AUTHORIZED REPRESENTATIVE OF THE
31 DETERMINATION OF THE INVESTIGATOR; AND

32 (II) DISCONTINUE PARTICIPATION BY THE DECISIONALLY
33 INCAPACITATED INDIVIDUAL IN THE RESEARCH.

34 (C) (1) THIS SUBSECTION APPLIES WHEN A DECISIONALLY INCAPACITATED
35 INDIVIDUAL PARTICIPATES IN RESEARCH THAT, AS DETERMINED BY AN IRB,
36 PRESENTS A PARTICULAR LEVEL OF RISK TO THE DECISIONALLY INCAPACITATED
37 INDIVIDUAL.

1 (2) IF THE INVESTIGATOR DETERMINES THAT RESEARCH PRESENTS A
2 HIGHER LEVEL OF RISK TO A DECISIONALLY INCAPACITATED INDIVIDUAL THAN
3 THAT ORIGINALLY DETERMINED BY THE IRB, THE INVESTIGATOR SHALL:

4 (I) ADVISE THE LEGALLY AUTHORIZED REPRESENTATIVE OF THE
5 DETERMINATION OF THE INVESTIGATOR; AND

6 (II) DISCONTINUE PARTICIPATION BY THE DECISIONALLY
7 INCAPACITATED INDIVIDUAL IN THE RESEARCH.

8 (D) AN INVESTIGATOR IMMEDIATELY SHALL REPORT TO THE IRB ANY
9 UNEXPECTED SERIOUS HARM TO A DECISIONALLY INCAPACITATED INDIVIDUAL
10 RESULTING FROM PARTICIPATION IN THE RESEARCH.

11 (E) IN ADDITION TO THE REVIEW OF RESEARCH AT PERIODIC INTERVALS
12 REQUIRED BY THE COMMON RULE, AN IRB SHALL PROMPTLY CONSIDER WHETHER
13 TO SUSPEND OR WITHDRAW ITS APPROVAL OF RESEARCH OR SUSPEND THE
14 ACCRUAL OF AN ADDITIONAL RESEARCH SUBJECT IF THE IRB CONCLUDES THAT:

15 (1) CONTINUATION OF RESEARCH MAY RESULT IN UNANTICIPATED
16 HARM TO A DECISIONALLY INCAPACITATED INDIVIDUAL; OR

17 (2) AN INVESTIGATOR HAS FAILED TO:

18 (I) CARRY OUT PROPERLY THE RESPONSIBILITIES OF THE
19 INVESTIGATOR UNDER THE COMMON RULE AND THIS SUBTITLE; OR

20 (II) COMPLY WITH A DETERMINATION OF THE IRB.

21 (F) IF AN IRB SUSPENDS OR WITHDRAWS ITS APPROVAL OF RESEARCH OR
22 SUSPENDS THE ACCRUAL OF AN ADDITIONAL RESEARCH SUBJECT, THE IRB SHALL
23 NOTIFY THE SECRETARY AND THE ATTORNEY GENERAL OF ITS ACTION.

24 20-720.

25 IF A DECISIONALLY INCAPACITATED INDIVIDUAL MUST BE WITHDRAWN FROM
26 A STANDARD TREATMENT TO RECEIVE A TREATMENT UNDER INVESTIGATION OR BE
27 WITHDRAWN FROM A TREATMENT UNDER INVESTIGATION TO RETURN TO A
28 STANDARD TREATMENT, AN INVESTIGATOR SHALL:

29 (1) DESIGN THE TREATMENT WITHDRAWAL PHASE OF THE RESEARCH,
30 INCLUDING ITS DURATION, SO AS TO MINIMIZE THE RISK TO THE DECISIONALLY
31 INCAPACITATED INDIVIDUAL FROM THE WITHDRAWAL;

32 (2) IF THE PERIOD OF WITHDRAWAL OCCURS WHILE THE DECISIONALLY
33 INCAPACITATED INDIVIDUAL IS AN IN-PATIENT IN A HOSPITAL OR A RESIDENT OF A
34 HEALTH CARE FACILITY, ASSURE THE PROMPT AVAILABILITY OF MEDICAL CARE
35 THAT MAY BE NEEDED BY THE RESEARCH SUBJECT IN THE EVENT OF A MEDICALLY
36 SERIOUS SIDE EFFECT OF WITHDRAWAL; AND

1 (3) IN OTHER CIRCUMSTANCES, INFORM THE DECISIONALLY
2 INCAPACITATED INDIVIDUAL, THE LEGALLY AUTHORIZED REPRESENTATIVE, AND
3 ANY INDIVIDUAL WHO THE INVESTIGATOR KNOWS WILL BE PROVIDING CARE TO THE
4 DECISIONALLY INCAPACITATED INDIVIDUAL OF:

5 (I) ANY SPECIAL PRECAUTION THAT NEEDS TO BE TAKEN DURING
6 THE COURSE OF THE RESEARCH; AND

7 (II) THE MEANS TO OBTAIN TIMELY MEDICAL CARE THAT IS
8 APPROPRIATE TO THE NEEDS OF THE DECISIONALLY INCAPACITATED INDIVIDUAL
9 IN THE EVENT OF A MEDICALLY SERIOUS SIDE EFFECT OF WITHDRAWAL FROM A
10 TREATMENT.

11 20-721.

12 (A) THIS SECTION APPLIES IF A RESEARCH PROTOCOL:

13 (1) INVOLVES WITHDRAWING A GROUP OF DECISIONALLY
14 INCAPACITATED INDIVIDUALS FROM A STANDARD TREATMENT; OR

15 (2) HAS BEEN DETERMINED BY AN IRB TO PRESENT A LEVEL OF RISK
16 GREATER THAN A MINIMAL RISK.

17 (B) FOR A RESEARCH PROTOCOL SPECIFIED IN SUBSECTION (A) OF THIS
18 SECTION, A MEDICALLY RESPONSIBLE CLINICIAN SHALL BE DESIGNATED BY:

19 (1) THE IRB, IN ACCORDANCE WITH § 20-717(B) OF THIS SUBTITLE; OR

20 (2) THE INVESTIGATOR, IF THE IRB HAS NOT DESIGNATED A MEDICALLY
21 RESPONSIBLE CLINICIAN AND THE MEDICALLY RESPONSIBLE CLINICIAN IS:

22 (I) A DISINTERESTED INDIVIDUAL; AND

23 (II) APPROVED BY THE IRB.

24 (C) THE MEDICALLY RESPONSIBLE CLINICIAN SHALL, IN ACCORDANCE WITH
25 A PROCEDURE OR A REQUIREMENT SPECIFIED BY THE IRB:

26 (1) FOR A RESEARCH PROTOCOL THAT INVOLVES WITHDRAWING A
27 GROUP OF DECISIONALLY INCAPACITATED INDIVIDUALS FROM A STANDARD
28 TREATMENT:

29 (I) EVALUATE THE MEDICAL CONDITION OF EACH DECISIONALLY
30 INCAPACITATED INDIVIDUAL IN THAT GROUP BEFORE ENROLLMENT AND AT
31 APPROPRIATE INTERVALS DURING THE RESEARCH; AND

32 (II) CONSIDER WHETHER INVOLVEMENT IN THE RESEARCH
33 PRESENTS A RISK TO THE HEALTH OF THE DECISIONALLY INCAPACITATED
34 INDIVIDUAL THAT THE MEDICALLY RESPONSIBLE CLINICIAN CONSIDERS
35 MEDICALLY INADVISABLE;

1 (1) ANY MATERIAL RISK AND DIRECT MEDICAL BENEFIT REASONABLY
2 FORESEEABLE FROM PARTICIPATION IN THE RESEARCH;

3 (2) IF THE RESEARCH PROTOCOL INVOLVES AN ALTERNATIVE TO A
4 STANDARD FORM OF TREATMENT, THE RISK AND BENEFIT OF THE RESEARCH
5 ALTERNATIVE COMPARED TO THE STANDARD TREATMENT; AND

6 (3) RANDOMIZATION, THE USE OF A PLACEBO, OR OTHER ASPECTS OF
7 THE CONTROL ELEMENT OF A RESEARCH DESIGN.

8 (C) (1) BEFORE INVOLVING A DECISIONALLY INCAPACITATED INDIVIDUAL
9 IN RESEARCH, AN INVESTIGATOR SHALL OBTAIN THE INFORMED CONSENT OF A
10 LEGALLY AUTHORIZED REPRESENTATIVE AS PROVIDED IN THIS SUBTITLE, A COURT,
11 OR A GUARDIAN OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

12 (2) UNLESS AN IRB WAIVES DOCUMENTATION REQUIREMENTS UNDER
13 45 C.F.R. § 46.117(C), AN INVESTIGATOR SHALL DOCUMENT THE CONSENT BY
14 OBTAINING A WRITTEN CONSENT FORM SIGNED BY THE LEGALLY AUTHORIZED
15 REPRESENTATIVE.

16 (D) IF AN INDIVIDUAL IS A DECISIONALLY INCAPACITATED INDIVIDUAL
17 WHEN FIRST INVOLVED IN RESEARCH, BUT SUBSEQUENTLY IS ABLE TO GIVE
18 INFORMED CONSENT, THE INVESTIGATOR MAY NOT CONTINUE TO INVOLVE THE
19 INDIVIDUAL IN THE RESEARCH WITHOUT THE INFORMED CONSENT OF THE
20 INDIVIDUAL.

21 20-725.

22 (A) BEFORE PARTICIPATING IN RESEARCH INVOLVING A DECISIONALLY
23 INCAPACITATED INDIVIDUAL, AN INVESTIGATOR SHALL TELL THE DECISIONALLY
24 INCAPACITATED INDIVIDUAL, UNLESS THE DECISIONALLY INCAPACITATED
25 INDIVIDUAL IS UNCONSCIOUS, IN A MANNER APPROPRIATE TO THE CAPACITY OF
26 THE DECISIONALLY INCAPACITATED INDIVIDUAL FOR UNDERSTANDING:

27 (1) THE FACT THAT THE DECISIONALLY INCAPACITATED INDIVIDUAL IS
28 BEING ASKED TO PARTICIPATE IN RESEARCH;

29 (2) THE NATURE OF THE RESEARCH AND ITS LIKELY EFFECT ON THE
30 DECISIONALLY INCAPACITATED INDIVIDUAL;

31 (3) THE NAME OF THE LEGALLY AUTHORIZED REPRESENTATIVE WHO
32 HAS CONSENTED TO PARTICIPATION BY THE DECISIONALLY INCAPACITATED
33 INDIVIDUAL;

34 (4) THE FACT THAT, EXCEPT AS OTHERWISE ORDERED BY A COURT, THE
35 DECISIONALLY INCAPACITATED INDIVIDUAL MAY DECLINE TO PARTICIPATE IN THE
36 RESEARCH WITHOUT PENALTY OR LOSS OF BENEFITS TO WHICH THE DECISIONALLY
37 INCAPACITATED INDIVIDUAL IS OTHERWISE ENTITLED; AND

1 (5) THE FACT THAT, EXCEPT AS OTHERWISE ORDERED BY A COURT, IF
2 THE DECISIONALLY INCAPACITATED INDIVIDUAL AGREES TO PARTICIPATE IN THE
3 RESEARCH, THE DECISIONALLY INCAPACITATED INDIVIDUAL SUBSEQUENTLY MAY
4 WITHDRAW FROM THE RESEARCH WITHOUT PENALTY OR LOSS OF BENEFITS TO
5 WHICH THE DECISIONALLY INCAPACITATED INDIVIDUAL IS OTHERWISE ENTITLED.

6 (B) BEFORE INVOLVING A DECISIONALLY INCAPACITATED INDIVIDUAL IN
7 RESEARCH, AN INVESTIGATOR SHALL OBTAIN THE ASSENT OF THE DECISIONALLY
8 INCAPACITATED INDIVIDUAL IF THE DECISIONALLY INCAPACITATED INDIVIDUAL IS
9 CAPABLE OF GIVING ASSENT.

10 (C) AN INVESTIGATOR MAY TAKE REASONABLE, NONCOERCIVE STEPS TO
11 REQUEST A DECISIONALLY INCAPACITATED INDIVIDUAL TO RECONSIDER A
12 REFUSAL OF ASSENT OR REFUSAL TO PERFORM AN ACTION RELATED TO THE
13 RESEARCH.

14 20-726.

15 (A) IF A LEGALLY AUTHORIZED REPRESENTATIVE IS REQUIRED UNDER THIS
16 SUBTITLE TO CONSIDER WHETHER OR NOT A DECISIONALLY INCAPACITATED
17 INDIVIDUAL WOULD CONSENT TO PARTICIPATE IN RESEARCH IF THE DECISIONALLY
18 INCAPACITATED INDIVIDUAL WERE ABLE TO GIVE INFORMED CONSENT, THE
19 LEGALLY AUTHORIZED REPRESENTATIVE MAY TAKE INTO ACCOUNT ANY RELEVANT
20 INFORMATION, INCLUDING:

21 (1) ANY EXPRESSED PREFERENCE OF THE DECISIONALLY
22 INCAPACITATED INDIVIDUAL REGARDING PARTICIPATION IN THE TYPE OF
23 RESEARCH AT ISSUE;

24 (2) ANY EXPRESSED PREFERENCE OF THE DECISIONALLY
25 INCAPACITATED INDIVIDUAL ABOUT PARTICIPATION IN RESEARCH GENERALLY;

26 (3) ANY RELIGIOUS OR MORAL BELIEF OR PERSONAL VALUES OF THE
27 DECISIONALLY INCAPACITATED INDIVIDUAL CONCERNING PARTICIPATION IN
28 RESEARCH;

29 (4) ANY BEHAVIORAL OR OTHER MANIFESTATION OF THE ATTITUDE OF
30 THE DECISIONALLY INCAPACITATED INDIVIDUAL TOWARD PARTICIPATION IN
31 RESEARCH;

32 (5) ANY REACTION OF THE DECISIONALLY INCAPACITATED INDIVIDUAL
33 TO PARTICIPATION BY ANOTHER INDIVIDUAL IN RESEARCH; AND

34 (6) ANY STATEMENT OF THE DECISIONALLY INCAPACITATED
35 INDIVIDUAL ABOUT THE EFFECT OF PARTICIPATION IN RESEARCH BY THE
36 DECISIONALLY INCAPACITATED INDIVIDUAL ON THE FAMILY OF THE INDIVIDUAL OR
37 ON ANOTHER INDIVIDUAL WHO HAS THE SAME MEDICAL CONDITION.

38 (B) PRIOR PARTICIPATION BY A DECISIONALLY INCAPACITATED INDIVIDUAL
39 IN SIMILAR RESEARCH, IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WAS

1 ABLE TO GIVE INFORMED CONSENT, MAY BE TAKEN INTO ACCOUNT BY A LEGALLY
2 AUTHORIZED REPRESENTATIVE BUT MAY NOT BE THE SOLE BASIS ON WHICH
3 PERMISSION IS GRANTED FOR THE DECISIONALLY INCAPACITATED INDIVIDUAL TO
4 PARTICIPATE IN THE RESEARCH.

5 20-727.

6 (A) NOTWITHSTANDING THE AUTHORITY OF A LEGALLY AUTHORIZED
7 REPRESENTATIVE UNDER THIS SUBTITLE, IF A GUARDIAN OF THE PERSON IS
8 APPOINTED FOR A DECISIONALLY INCAPACITATED INDIVIDUAL AND HAS SPECIFIC
9 AUTHORITY TO MAKE A DECISION ABOUT PARTICIPATION BY THE DECISIONALLY
10 INCAPACITATED INDIVIDUAL IN RESEARCH, THE GUARDIAN, SUBJECT TO THE
11 SUPERVISION OF A COURT, HAS EXCLUSIVE AUTHORITY TO MAKE THE DECISION.

12 (B) A GUARDIAN OF THE PERSON MAY NOT GIVE INFORMED CONSENT FOR A
13 DECISIONALLY INCAPACITATED INDIVIDUAL TO PARTICIPATE IN RESEARCH UNLESS
14 THE RESEARCH, AS APPROVED BY THE IRB, PRESENTS:

15 (1) A REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO THE
16 DECISIONALLY INCAPACITATED INDIVIDUAL; OR

17 (2) NO MORE THAN A MINOR INCREASE OVER A MINIMAL RISK TO THE
18 DECISIONALLY INCAPACITATED INDIVIDUAL.

19 20-728.

20 (A) A LEGALLY AUTHORIZED REPRESENTATIVE WHO CONSENTS TO
21 PARTICIPATION BY A DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH
22 SHALL:

23 (1) TAKE REASONABLE STEPS TO LEARN WHETHER THE EXPERIENCE
24 OF THE DECISIONALLY INCAPACITATED INDIVIDUAL IN THE RESEARCH IS
25 CONSISTENT WITH THE EXPECTATION OF THE LEGALLY AUTHORIZED
26 REPRESENTATIVE AT THE TIME THE CONSENT WAS GRANTED, INCLUDING AN
27 EXPECTATION ABOUT ANY POTENTIAL BENEFIT OR RISK PRESENTED BY THE
28 RESEARCH; AND

29 (2) WITHDRAW CONSENT IF:

30 (I) THE RESEARCH PROTOCOL WAS INITIALLY DETERMINED TO
31 PRESENT A REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO A
32 DECISIONALLY INCAPACITATED INDIVIDUAL BUT PARTICIPATION IN RESEARCH NO
33 LONGER DOES SO FOR THE DECISIONALLY INCAPACITATED INDIVIDUAL;

34 (II) PARTICIPATION IN RESEARCH PRESENTS A HIGHER LEVEL OF
35 RISK TO THE DECISIONALLY INCAPACITATED INDIVIDUAL THAN INITIALLY
36 EXPECTED; OR

1 (III) CONSIDERING ALL RELEVANT CIRCUMSTANCES, CONTINUED
2 PARTICIPATION WOULD BE DETRIMENTAL TO THE WELL-BEING OF THE
3 DECISIONALLY INCAPACITATED INDIVIDUAL.

4 (B) IF AN INDIVIDUAL GIVES INFORMED CONSENT TO PARTICIPATION IN
5 RESEARCH BUT BECOMES A DECISIONALLY INCAPACITATED INDIVIDUAL DURING
6 THE COURSE OF THE RESEARCH, A LEGALLY AUTHORIZED REPRESENTATIVE SHALL
7 WITHDRAW CONSENT FOR THE CONTINUED PARTICIPATION BY THE DECISIONALLY
8 INCAPACITATED INDIVIDUAL IN THE RESEARCH IF, CONSIDERING ALL RELEVANT
9 CIRCUMSTANCES, CONTINUED PARTICIPATION WOULD BE DETRIMENTAL TO THE
10 WELL-BEING OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

11 20-729. RESERVED.

12 20-730. RESERVED.

13 PART VI. CONSENT - RESEARCH INVOLVING DIRECT MEDICAL BENEFIT OR
14 MINIMAL RISK.

15 20-731.

16 THIS PART APPLIES TO RESEARCH CONDUCTED UNDER A RESEARCH PROTOCOL
17 THAT, AS DETERMINED BY AN IRB, PRESENTS:

18 (1) A REASONABLE PROSPECT OF DIRECT MEDICAL BENEFIT TO A
19 DECISIONALLY INCAPACITATED INDIVIDUAL WHO IS A RESEARCH SUBJECT; OR

20 (2) A MINIMAL RISK TO A DECISIONALLY INCAPACITATED INDIVIDUAL
21 WHO IS A RESEARCH SUBJECT.

22 20-732.

23 (A) A RESEARCH AGENT MAY CONSENT TO PARTICIPATION BY A
24 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-730 OF
25 THIS SUBTITLE IF THE RESEARCH AGENT HAS REASON TO BELIEVE THAT THE
26 DECISIONALLY INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO PARTICIPATE
27 IN THE RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WERE ABLE
28 TO GIVE INFORMED CONSENT.

29 (B) (1) THIS SUBSECTION APPLIES IF:

30 (I) A RESEARCH AGENT CAN NOT GIVE CONSENT UNDER
31 SUBSECTION (A) OF THIS SECTION; AND

32 (II) THE RESEARCH PRESENTS A REASONABLE PROSPECT OF
33 DIRECT MEDICAL BENEFIT.

34 (2) THE RESEARCH AGENT MAY CONSENT TO PARTICIPATION BY A
35 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH IF THE RESEARCH AGENT

1 CONCLUDES THAT PARTICIPATION IN THE RESEARCH IS IN THE MEDICAL BEST
2 INTEREST OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

3 20-733.

4 (A) A HEALTH CARE AGENT MAY CONSENT TO PARTICIPATION BY A
5 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-731 OF
6 THIS SUBTITLE IF:

7 (1) A RESEARCH AGENT IS NOT AVAILABLE; AND

8 (2) THE HEALTH CARE AGENT HAS REASON TO BELIEVE THAT THE
9 DECISIONALLY INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO PARTICIPATE
10 IN THE RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WERE ABLE
11 TO GIVE INFORMED CONSENT.

12 (B) (1) THIS SUBSECTION APPLIES IF:

13 (I) A HEALTH CARE AGENT CAN NOT GIVE CONSENT UNDER
14 SUBSECTION (A)(2) OF THIS SECTION; AND

15 (II) THE RESEARCH PRESENTS A REASONABLE PROSPECT OF
16 DIRECT MEDICAL BENEFIT.

17 (2) THE HEALTH CARE AGENT MAY CONSENT TO PARTICIPATION BY A
18 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH IF THE HEALTH CARE
19 AGENT CONCLUDES THAT PARTICIPATION IN THE RESEARCH IS IN THE MEDICAL
20 BEST INTEREST OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

21 20-734.

22 (A) A SURROGATE MAY CONSENT TO PARTICIPATION BY A DECISIONALLY
23 INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-731 OF THIS SUBTITLE
24 IF:

25 (1) NEITHER A RESEARCH AGENT NOR A HEALTH CARE AGENT IS
26 AVAILABLE; AND

27 (2) THE SURROGATE HAS REASON TO BELIEVE THAT THE
28 DECISIONALLY INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO PARTICIPATE
29 IN THE RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WERE ABLE
30 TO GIVE INFORMED CONSENT.

31 (B) (1) THIS SUBSECTION APPLIES IF:

32 (I) A SURROGATE CAN NOT GIVE CONSENT UNDER SUBSECTION
33 (A)(2) OF THIS SECTION; AND

34 (II) THE RESEARCH PRESENTS A REASONABLE PROSPECT OF
35 DIRECT MEDICAL BENEFIT.

1 (2) THE SURROGATE MAY CONSENT TO PARTICIPATION BY A
2 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH IF THE SURROGATE
3 CONCLUDES THAT PARTICIPATION IN THE RESEARCH IS IN THE MEDICAL BEST
4 INTEREST OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

5 (C) IF SURROGATES WITH EQUAL DECISION MAKING PRIORITY UNDER THE
6 HEALTH CARE DECISIONS ACT DISAGREE ABOUT PARTICIPATION BY A
7 DECISIONALLY INCAPACITATED INDIVIDUAL IN THE RESEARCH, THE
8 DISAGREEMENT SHALL BE RESOLVED IN ACCORDANCE WITH § 5-605(B) OF THIS
9 ARTICLE.

10 20-735.

11 (A) A PROXY DECISION MAKER DESIGNATED BY AN IRB UNDER § 20-717(B) OF
12 THIS SUBTITLE MAY CONSENT TO PARTICIPATION BY A DECISIONALLY
13 INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-731 OF THIS SUBTITLE
14 IF:

15 (1) A RESEARCH AGENT, HEALTH CARE AGENT, OR SURROGATE IS NOT
16 AVAILABLE; AND

17 (2) THE RESEARCH IS UNAMBIGUOUSLY INCLUDED IN AN ADVANCE
18 DIRECTIVE OF THE DECISIONALLY INCAPACITATED INDIVIDUAL AND THE ADVANCE
19 DIRECTIVE AUTHORIZES PARTICIPATION IN RESEARCH.

20 (B) (1) THIS SUBSECTION APPLIES IF:

21 (I) A PROXY DECISION MAKER CAN NOT GIVE CONSENT ON THE
22 BASIS OF SUBSECTION (A)(2) OF THIS SECTION; AND

23 (II) THE RESEARCH PRESENTS A REASONABLE PROSPECT OF
24 DIRECT MEDICAL BENEFIT.

25 (2) A PROXY DECISION MAKER MAY CONSENT TO PARTICIPATION BY A
26 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH IF THE PROXY DECISION
27 MAKER CONCLUDES THAT PARTICIPATION IN THE RESEARCH IS IN THE MEDICAL
28 BEST INTEREST OF THE DECISIONALLY INCAPACITATED INDIVIDUAL.

29 20-736. RESERVED.

30 20-737. RESERVED.

31 PART VII. CONSENT - RESEARCH INVOLVING NO DIRECT MEDICAL
32 BENEFIT AND A MINOR INCREASE OVER MINIMAL RISK.

33 20-738.

34 THIS PART APPLIES TO RESEARCH CONDUCTED UNDER A RESEARCH PROTOCOL
35 THAT, AS DETERMINED BY AN IRB:

1 (1) DOES NOT PRESENT A REASONABLE PROSPECT OF DIRECT MEDICAL
2 BENEFIT TO A DECISIONALLY INCAPACITATED INDIVIDUAL WHO IS A RESEARCH
3 SUBJECT; AND

4 (2) PRESENTS A MINOR INCREASE OVER A MINIMAL RISK TO A
5 DECISIONALLY INCAPACITATED INDIVIDUAL WHO IS A RESEARCH SUBJECT.

6 20-739.

7 A RESEARCH AGENT MAY CONSENT TO PARTICIPATION BY A DECISIONALLY
8 INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-738 OF THIS SUBTITLE
9 IF THE RESEARCH AGENT CONCLUDES, BASED ON AN ADVANCE DIRECTIVE
10 AUTHORIZING PARTICIPATION IN RESEARCH AND OTHER PERTINENT INFORMATION,
11 THAT THE DECISIONALLY INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO
12 PARTICIPATE IN THE RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL
13 WERE ABLE TO GIVE INFORMED CONSENT.

14 20-740.

15 A HEALTH CARE AGENT MAY CONSENT TO PARTICIPATION BY A DECISIONALLY
16 INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-738 OF THIS SUBTITLE
17 IF:

18 (1) A RESEARCH AGENT IS NOT AVAILABLE; AND

19 (2) BASED ON DIRECT AND EXPLICIT EVIDENCE OF THE WISH OF THE
20 DECISIONALLY INCAPACITATED INDIVIDUAL TO PARTICIPATE IN THE RESEARCH AS
21 DOCUMENTED IN ACCORDANCE WITH A STANDARD AND PROCEDURE DETERMINED
22 BY AN IRB, THE HEALTH CARE AGENT CONCLUDES THAT THE DECISIONALLY
23 INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO PARTICIPATE IN THE
24 RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WERE ABLE TO GIVE
25 INFORMED CONSENT.

26 20-741.

27 ONLY A LEGALLY AUTHORIZED REPRESENTATIVE WHO IS A RESEARCH AGENT
28 OR A HEALTH CARE AGENT MAY CONSENT TO PARTICIPATION BY A DECISIONALLY
29 INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-738 OF THIS
30 SUBTITLE.

31 20-742. RESERVED.

32 20-743. RESERVED.

1 PART VIII. CONSENT - RESEARCH INVOLVING NO DIRECT MEDICAL BENEFIT AND
2 MORE THAN A MINOR INCREASE OVER MINIMAL RISK.

3 20-744.

4 THIS PART APPLIES TO RESEARCH CONDUCTED PURSUANT TO A RESEARCH
5 PROTOCOL THAT, AS DETERMINED BY AN IRB:

6 (1) DOES NOT PRESENT A REASONABLE PROSPECT OF DIRECT MEDICAL
7 BENEFIT TO A DECISIONALLY INCAPACITATED INDIVIDUAL WHO IS A RESEARCH
8 SUBJECT; AND

9 (2) PRESENTS MORE THAN A MINOR INCREASE OVER A MINIMAL RISK
10 TO A DECISIONALLY INCAPACITATED INDIVIDUAL WHO IS A RESEARCH SUBJECT.

11 20-745.

12 (A) A RESEARCH AGENT MAY CONSENT TO PARTICIPATION BY A
13 DECISIONALLY INCAPACITATED INDIVIDUAL IN RESEARCH SPECIFIED IN § 20-744 OF
14 THIS SUBTITLE IF:

15 (1) A MONITOR CONFIRMS THAT:

16 (I) THE RESEARCH IS UNAMBIGUOUSLY INCLUDED IN A
17 RESEARCH ADVANCE DIRECTIVE OF THE DECISIONALLY INCAPACITATED
18 INDIVIDUAL; AND

19 (II) THE RESEARCH AGENT UNDERSTANDS THE GOAL AND RISK OF
20 THE RESEARCH; AND

21 (2) BASED ON THE RESEARCH ADVANCE DIRECTIVE AND OTHER
22 PERTINENT INFORMATION, THE RESEARCH AGENT CONCLUDES THAT THE
23 DECISIONALLY INCAPACITATED INDIVIDUAL WOULD HAVE AGREED TO PARTICIPATE
24 IN THE RESEARCH IF THE DECISIONALLY INCAPACITATED INDIVIDUAL WERE ABLE
25 TO GIVE INFORMED CONSENT.

26 (B) A MONITOR SHALL WITNESS THE PROCESS BY WHICH AN INVESTIGATOR
27 PROVIDES THE RESEARCH AGENT WITH THE INFORMATION REQUIRED BY AN IRB
28 FOR INFORMED CONSENT.

29 20-746.

30 ONLY A LEGALLY AUTHORIZED REPRESENTATIVE WHO IS A RESEARCH AGENT
31 MAY CONSENT TO PARTICIPATION BY A DECISIONALLY INCAPACITATED INDIVIDUAL
32 IN RESEARCH SPECIFIED IN § 20-744 OF THIS SUBTITLE.

1 20-747. RESERVED.

2 20-748. RESERVED.

3 PART IX. PUBLIC INFORMATION AND ACCOUNTABILITY.

4 20-749.

5 (A) (1) FOR RESEARCH APPROVED BY AN IRB ON OR AFTER OCTOBER 1, 1999,
6 INVOLVING A DECISIONALLY INCAPACITATED INDIVIDUAL, THE IRB SHALL ASSURE
7 THAT ANY MEMBER OF THE PUBLIC ON REQUEST MAY OBTAIN A COPY OF:

8 (I) THE RELEVANT PORTIONS OF THE MINUTES OF THE IRB;

9 (II) IF NOT INCLUDED IN THE MINUTES OF THE IRB, A SUMMARY OF
10 THE RESEARCH PROTOCOL; AND

11 (III) A WRITTEN INFORMED CONSENT DOCUMENT APPROVED BY
12 THE IRB.

13 (2) DISCLOSURE OF A DOCUMENT SPECIFIED IN PARAGRAPH (1) OF THIS
14 SUBSECTION MAY BE MADE BY THE IRB OR, UNDER AN AGREEMENT WITH THE IRB,
15 BY AN INVESTIGATOR, A SPONSOR OF RESEARCH, OR AN INSTITUTION WITH WHICH
16 THE IRB IS AFFILIATED.

17 (3) THE PERSON RESPONSIBLE FOR DISCLOSURE MAY CHARGE A
18 REASONABLE FEE FOR COPIES.

19 (B) A DISCLOSURE REQUIRED BY SUBSECTION (A) OF THIS SECTION IS IN
20 ADDITION TO ANY DISCLOSURE OF INFORMATION OR DOCUMENT RELATED TO
21 RESEARCH THAT IS REQUIRED OR AUTHORIZED BY:

22 (1) A STATUTE, REGULATION, OR POLICY OF THE FEDERAL
23 GOVERNMENT OR OF THIS STATE; OR

24 (2) A POLICY OF AN IRB, A SPONSOR OF RESEARCH, AN INSTITUTION
25 WITH WHICH THE IRB IS AFFILIATED, OR AN INSTITUTION AT WHICH RESEARCH
26 OCCURS.

27 20-750.

28 NOT LATER THAN FEBRUARY 15 OF EACH YEAR BEGINNING IN 2000, AN IRB
29 THAT, DURING THE PRECEDING CALENDAR YEAR, APPROVED RESEARCH IN WHICH A
30 DECISIONALLY INCAPACITATED INDIVIDUAL WAS INTENDED TO BE A SUBJECT OF
31 RESEARCH SHALL REPORT TO THE SECRETARY AND TO THE ATTORNEY GENERAL:

32 (1) THE TITLE OF EACH RESEARCH PROTOCOL APPROVED BY THE IRB;

33 (2) THE NUMBER OF DECISIONALLY INCAPACITATED INDIVIDUALS WHO
34 WERE AUTHORIZED TO BECOME RESEARCH SUBJECTS IN EACH PROTOCOL;

1 (C) THE SECRETARY SHALL MAKE AVAILABLE TO THE PUBLIC THE RESULTS
2 OF ANY STUDY CONDUCTED UNDER THIS SECTION.

3 20-756. RESERVED.

4 20-757. RESERVED.

5 PART XI. IMMUNITY AND LIABILITY.

6 20-758.

7 (A) THIS SECTION MAY NOT APPLY TO AN INDIVIDUAL WHO, BY A
8 PREPONDERANCE OF THE EVIDENCE, FAILS TO COMPLY IN GOOD FAITH WITH THIS
9 SUBTITLE.

10 (B) (1) THIS SUBSECTION MAY NOT AFFECT THE LIABILITY OF AN
11 INVESTIGATOR FOR ANY ACTION OF THE INVESTIGATOR, EXCEPT FOR AN ACTION OF
12 AN INVESTIGATOR IN CONDUCTING RESEARCH WITHOUT THE INFORMED CONSENT
13 OF AN INDIVIDUAL WHO IS A RESEARCH SUBJECT AS AUTHORIZED UNDER THIS
14 SUBTITLE.

15 (2) IF RESEARCH INVOLVING A DECISIONALLY INCAPACITATED
16 INDIVIDUAL IS AUTHORIZED UNDER THIS SUBTITLE, AN INVESTIGATOR IS NOT
17 SUBJECT TO CRIMINAL PROSECUTION OR CIVIL LIABILITY OR DEEMED TO HAVE
18 ENGAGED IN UNPROFESSIONAL CONDUCT SOLELY AS A RESULT OF CONDUCTING
19 THE RESEARCH WITHOUT THE INFORMED CONSENT OF THE DECISIONALLY
20 INCAPACITATED INDIVIDUAL.

21 (C) A LEGALLY AUTHORIZED REPRESENTATIVE WHO, AS AUTHORIZED UNDER
22 THIS SUBTITLE, CONSENTS TO PARTICIPATION BY A DECISIONALLY INCAPACITATED
23 INDIVIDUAL IN RESEARCH IS NOT SUBJECT TO:

24 (1) CRIMINAL PROSECUTION OR CIVIL LIABILITY FOR GIVING THAT
25 CONSENT; OR

26 (2) LIABILITY FOR ANY COST ASSOCIATED WITH THE PARTICIPATION IN
27 RESEARCH BASED SOLELY ON THE CONSENT OF THE LEGALLY AUTHORIZED
28 REPRESENTATIVE.

29 (D) A MEMBER OF AN IRB, A MONITOR, OR A MEDICALLY RESPONSIBLE
30 CLINICIAN IS NOT SUBJECT TO CRIMINAL PROSECUTION OR CIVIL LIABILITY OR
31 DEEMED TO HAVE ENGAGED IN UNPROFESSIONAL CONDUCT AS A RESULT OF AN
32 ACTION PERFORMED BY THE MEMBER OF THE IRB, A MONITOR, OR A MEDICALLY
33 RESPONSIBLE CLINICIAN IN ACCORDANCE WITH THIS SUBTITLE.

34 20-759.

35 (A) NOTWITHSTANDING ANY OTHER PROVISION OF THIS PART, AN
36 INVESTIGATOR WHO KNOWINGLY INVOLVES A DECISIONALLY INCAPACITATED

1 INDIVIDUAL IN RESEARCH IN VIOLATION OF THIS SUBTITLE IS SUBJECT TO
2 CRIMINAL PROSECUTION OR CIVIL LIABILITY AS OTHERWISE PROVIDED BY LAW.

3 (B) AN INVESTIGATOR WHO KNOWINGLY INVOLVES A DECISIONALLY
4 INCAPACITATED INDIVIDUAL IN RESEARCH IN VIOLATION OF THIS SUBTITLE SHALL
5 BE DEEMED TO HAVE ENGAGED IN UNPROFESSIONAL CONDUCT FOR PURPOSES OF
6 DISCIPLINARY ACTION BY A LICENSING AUTHORITY.

7 (C) AN INVESTIGATOR WHO KNOWINGLY AND WILLFULLY CONDUCTS
8 RESEARCH THAT HAS BEEN SUSPENDED OR TERMINATED BY AN IRB OR BY THE
9 SECRETARY IS GUILTY OF A MISDEMEANOR AND ON CONVICTION IS SUBJECT TO A
10 FINE NOT EXCEEDING \$10,000 OR IMPRISONMENT NOT EXCEEDING 12 MONTHS OR
11 BOTH.

12 20-760. RESERVED.

13 20-761. RESERVED.

14 PART XII. MISCELLANEOUS.

15 20-762.

16 A RESEARCH ADVANCE DIRECTIVE MADE BEFORE OCTOBER 1, 1999, SHALL BE
17 GIVEN EFFECT AS PROVIDED IN THIS SUBTITLE.

18 20-763.

19 THE ATTORNEY GENERAL SHALL PREPARE AND DISSEMINATE TO THE PUBLIC A
20 SUMMARY OF THE PROVISIONS OF THIS SUBTITLE.

21 20-764.

22 THIS SUBTITLE MAY BE CITED AS "THE DECISIONALLY INCAPACITATED
23 RESEARCH SUBJECT PROTECTION ACT."

24 20-765. RESERVED.

25 20-766. RESERVED.

26 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
27 October 1, 1999.